Everyone or Just Some? Cost-Effectiveness of General Population Versus Targeted Screening Strategies for Type 1 Diabetes in Canada
Authors' conclusion
General population screening detects more at-risk children than targeted approaches but also incurs higher costs. The incremental cost per case detected is comparable to that reported for other pediatric screening initiatives.
Study context
- Population
- Simulated children in Canada screened for T1D autoantibodies
- Comparison
- General population vs targeted (high genetic risk or family history) autoantibody screening for T1D, once at age 4 or at ages 2 and 6, vs no screening
- Outcome
- Incremental cost per at-risk child detected (effectiveness = number of at-risk children detected)
Methodological detailshybrid decision tree-Markov model, Canadian health system perspective, Costs from the Canadian health system perspective
- Hybrid decision tree-Markov model
- Canadian health system perspective
- Costs from the Canadian health system perspective
Main finding
As reported in the abstract
Incremental cost-effectiveness ratio
$11,383/case detected
General population, age 4 vs Family history, ages 2 and 6 · cost $404,534 more; detected 35 more cases per 10,000 children
Incremental cost per case detected
$25,923/case detected
General population, ages 2 and 6 vs General population, age 4 · additional cost $462,679; detected 18 more cases per 10,000 children
Original publication
Everyone or Just Some? Cost-Effectiveness of General Population Versus Targeted Screening Strategies for Type 1 Diabetes in Canada. Diabetes Care. Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →